Kenneth B. Newman
Corporate Officer/Principal presso IONIS PHARMACEUTICALS, INC.
Provenienza dei contatti di primo grado di Kenneth B. Newman
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 32 | |
| Public Company | Pharmaceuticals: Major | 14 | |
Mesoblast, Inc.
 Mesoblast, Inc. Pharmaceuticals: MajorHealth Technology Mesoblast, Inc. manufactures and distributes biopharmaceutical products. It develops cellular medicines for under-served therapeutic areas including cardiac diseases, spine orthopedic disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. The company was founded by Michael Schuster and Silviu Itescu in 2004 and is headquartered in New York, NY.
1
| Subsidiary | Pharmaceuticals: Major | 1 |
Acton Pharmaceuticals, Inc.
 Acton Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Acton Pharmaceuticals, Inc. developed and commercialized pharmaceutical products. The company was founded by John W. Simon and Daniel L. Kreisler in 2008 and is headquartered in Marlborough, MA.
1
| Subsidiary | Pharmaceuticals: Major | 1 |
Boehringer Ingelheim Corp.
 Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT.
1
| Subsidiary | Pharmaceuticals: Major | 1 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Kenneth B. Newman tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| ALZA CORPORATION | Pharmaceuticals: Major | Corporate Officer/Principal | |
SEQUUS Pharmaceuticals, Inc.
 SEQUUS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SEQUUS Pharmaceuticals, Inc. is based in Menlo Park, CA. Part of Johnson & Johnson, SEQUUS Pharmaceuticals, Inc. is a company that markets lipid-based biopharmaceutical products mainly to treat cancer and infectious diseases. SEQUUS Pharmaceuticals was acquired by ALZA Corp., part of Johnson & Johnson from June 22, 2001 on March 16, 1999 for $658.03 million. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Pharmaceuticals: Generic | Chief Tech/Sci/R&D Officer | |
| SOLENO THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Corporate Officer/Principal Masters Business Admin | |
| University of Pennsylvania | College/University | Doctorate Degree Doctorate Degree | |
| OXFORD BIOMEDICA PLC | Biotechnology | Director/Board Member | |
| National University of Singapore | College/University | Corporate Officer/Principal | |
| Imperial College London | College/University | Doctorate Degree | |
Institute of Chartered Accountants in England & Wales
 Institute of Chartered Accountants in England & Wales Miscellaneous Commercial ServicesCommercial Services The Institute of Chartered Accountants in England & Wales ensures that its members, students, and affiliates maintain the highest standards of professional competency and conduct to protect the public interest. The non-profit company is based in London, UK, and has subsidiaries in the United Kingdom. With over 150,000 members, the institute provides technical information, helplines, and communities to its members. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
Xention Pharma Ltd.
 Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | Pharmaceuticals: Major | Director/Board Member | |
| City of London (Great Britain) | Municipality | Corporate Officer/Principal | |
Warner Lambert (UK) Ltd.
 Warner Lambert (UK) Ltd. Pharmaceuticals: MajorHealth Technology Part of Pfizer Inc., Warner Lambert (UK) Ltd. is a manufacturer and wholesaler of pharmaceuticals and over the counter medicines. The company is based in Eastleigh, UK. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Andera Partners SCA
 Andera Partners SCA Investment ManagersFinance Andera Partners SCA (Andera Partners) is a private equity firm founded in 2001 by Pierre-Michel Passy. The firm is headquartered in Paris, France. | Investment Managers | Consultant / Advisor | |
| The University of Texas at Austin | College/University | Doctorate Degree Doctorate Degree | |
| Yale University | College/University | Graduate Degree Undergraduate Degree Graduate Degree | |
| University of British Columbia | College/University | Corporate Officer/Principal Doctorate Degree | |
| University of Michigan | College/University | Doctorate Degree Doctorate Degree | |
| University of San Diego | College/University | Masters Business Admin | |
| University of Cape Town | College/University | Doctorate Degree | |
| Baylor College of Medicine | College/University | Doctorate Degree Corporate Officer/Principal | |
Agency for Science, Technology & Research
 Agency for Science, Technology & Research Miscellaneous Commercial ServicesCommercial Services Agency for Science, Technology & Research engages in fostering scientific research and development. It is the agency for fostering world-class scientific research and talent for a vibrant knowledge-based and innovation-driven Singapore. The company was founded in 1991 and is headquartered in Singapore. | Miscellaneous Commercial Services | Director/Board Member | |
Cooley LLP
 Cooley LLP Miscellaneous Commercial ServicesCommercial Services Cooley LLP engages in the provision of legal services. It offers strategic litigation and business transaction services and is a representative of private and public companies, financial institutions, venture capital firms and nonprofit organizations. Its practices include commercial litigation; patent counseling and prosecution; employment and labor; asset recovery; and estate planning and personal representation. The company was founded in 1920 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Private Equity Investor | |
| King's College London | College/University | Corporate Officer/Principal Undergraduate Degree | |
Michael Smith Foundation for Health Research
 Michael Smith Foundation for Health Research Investment Trusts/Mutual FundsMiscellaneous The Michael Smith Foundation for Health Research operates as a health research funding agency. The non-profit company is based in Vancouver, Canada. Diane Finegood has been the CEO of the Canadian company since 2012. | Investment Trusts/Mutual Funds | Director/Board Member | |
Canadian Genetics Diseases Network
 Canadian Genetics Diseases Network Miscellaneous Commercial ServicesCommercial Services Canadian Genetics Diseases Network provides research and development services to the healthcare industry. The company is headquartered in Vancouver, Canada. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
Oligonucleotide Therapeutics Society, Inc.
 Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | Miscellaneous Commercial Services | Director/Board Member President | |
Royal Society of Canada
 Royal Society of Canada Miscellaneous Commercial ServicesCommercial Services The Royal Society of Canada offers educational courses. The non-profit company is based in Ottawa, Canada. The CEO of the Canadian company is Iris Almeida-Cote. | Miscellaneous Commercial Services | Director/Board Member | |
| Centre for Molecular Medicine & Therapeutic | Founder | ||
Xention Ltd.
 Xention Ltd. Pharmaceuticals: MajorHealth Technology Part of Xention Pharma Ltd., Xention Ltd. is a British company that develops and researches drugs. The company is based in Newmarket, UK. Xention was founded in 2002. | Pharmaceuticals: Major | Director/Board Member | |
NeuroVir Therapeutic, Inc.
 NeuroVir Therapeutic, Inc. Pharmaceuticals: MajorHealth Technology Part of MediGene AG, NeuroVir Therapeutic, Inc. develops herpes simplex virus technologies for the treatment of tumors and for gene delivery. The company is based in San Diego, CA. The company was founded by Michael R. Hayden, Frank Tufaro. NeuroVir Therapeutic was acquired by MediGene AG on January 12, 2001 for $53 million. | Pharmaceuticals: Major | Founder | |
| AURINIA PHARMACEUTICALS INC. | Biotechnology | Director/Board Member | |
| Harvard College | College/University | Undergraduate Degree Undergraduate Degree | |
| ABZENA PLC | Biotechnology | Chairman | |
| ABCELLERA BIOLOGICS INC. | Biotechnology | Director/Board Member | |
| AKCEA THERAPEUTICS, INC. | Pharmaceuticals: Major | Director of Finance/CFO President Director/Board Member Chairman Director/Board Member Corporate Officer/Principal | |
Medherant Ltd.
 Medherant Ltd. Pharmaceuticals: MajorHealth Technology Medherant Ltd. develops transdermal drug delivery patches. It offers transdermal drug patches for skin surface and are being used increasingly for pharmaceutical products such as analgesics, alzheimer's, smoking cessation, and hormone therapy. The company was founded by David Haddleton on April 2, 2014 and is headquartered in Coventry, the United Kingdom. | Pharmaceuticals: Major | Chairman | |
| Translational Laboratory in Genetic Medicine | Director/Board Member | ||
| Sunergos Innovations Ltd. | Director/Board Member | ||
Ascension Healthcare Plc
 Ascension Healthcare Plc Pharmaceuticals: MajorHealth Technology Ascension Healthcare Plc manufactures pharmaceutical products. The company was founded on September 25, 2013 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Flamingo Therapeutics BV
 Flamingo Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Flamingo Therapeutics BV is a Belgian company that specializes in developing RNA-targeted therapies for oncology. The company is based in Leuven, Belgium and was founded by Mike Garrett and Floor Stam. Flamingo is dedicated to delivering therapeutic benefit to patients living with cancer and believes that their programs and approach can successfully address large unmet medical needs where RNA-targeting can be effective. The company's clinical-stage pipeline focuses on targeting undruggable transcription factors and splice variants. The CEO is Stephane van Rooijen. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| BCLS ACQUISITION CORP. | Financial Conglomerates | Director/Board Member Director/Board Member | |
Prilenia Therapeutics Development Ltd.
 Prilenia Therapeutics Development Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Prilenia Therapeutics BV, Prilenia Therapeutics Development Ltd. is a clinical stage biotech company based in Herzliya, Israel. Prilenia Therapeutics is developing its lead drug candidate, pridopidine, which is a sigma-1 receptor agonist and is in clinical development for the treatment of ALS and Huntington's disease. Pridopidine is currently part of the Healey ALS platform phase 2/3 clinical study and is in a phase 3 trial (PROOF-HD) with the Huntington Study Group, addressing functional capacity in early-stage HD patients. The pridopidine pipeline includes further indications in the pre-clinical phase. The Israeli company was founded by Michael R. Hayden in 2018 with the purpose of developing treatments for neurodegenerative and neurodevelopmental disorders. | Miscellaneous Commercial Services | Founder | |
Prilenia Therapeutics BV
 Prilenia Therapeutics BV BiotechnologyHealth Technology Prilenia Therapeutics BV develops and manufactures pharmaceuticals. The company was founded in 2018 and is headquartered in Naarden, the Netherlands. | Biotechnology | Founder | |
| 89BIO, INC. | Pharmaceuticals: Major | Founder |
Statistiche
Distribuzione geografica
| Stati Uniti | 19 |
| Regno Unito | 14 |
| Canada | 9 |
| Singapore | 4 |
| Israele | 3 |
Settori
| Health Technology | 20 |
| Consumer Services | 14 |
| Commercial Services | 9 |
| Finance | 4 |
| Non-Energy Minerals | 2 |
Posizioni
| Director/Board Member | 220 |
| Corporate Officer/Principal | 110 |
| Independent Dir/Board Member | 58 |
| Chairman | 28 |
| Undergraduate Degree | 25 |
Contatti più connessi
| Insiders | |
|---|---|
| Trevor Jones | 36 |
| Mahendra Shah | 34 |
| Rishi Gupta | 29 |
| Michael Hayden | 27 |
| Joan Herman | 27 |
| Joseph Loscalzo | 25 |
| Joseph Klein | 24 |
| Sven Anders Ullman | 19 |
| Piers John Morgan | 18 |
| Ken Cunningham Cunningham | 17 |
| B. Parshall | 17 |
| Joseph Wender | 16 |
| Andrew Sinclair | 14 |
| Allene Diaz | 14 |
| Brett Monia | 13 |
- Borsa valori
- Insiders
- Kenneth B. Newman
- Connessioni Società
